Skip to content

Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular Characterization

Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular Characterization

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03486262
Acronym
K-FPI
Enrollment
100
Registered
2018-04-03
Start date
2018-02-01
Completion date
2020-02-29
Last updated
2018-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer and Idiopathic Pulmonary Fibrosis

Keywords

Lung cancer; Idiopathic pulmonary fibrosis

Brief summary

Retrospective inclusion of lung cancers developed in a context of idiopathic pulmonary fibrosis, diagnosed and / or treated in participating centers. The cases are recovered retrospectively from the records of the pulmonology and pathology departments of our various partners.

Detailed description

Primary objective: Characterize altered molecular pathways in lung cancer in patients with IPF versus lung cancer in non-IPF patients. Secondary objectives: Identify specific therapeutic targets Describe a cohort of lung cancers on IPF (clinical / radiological and pathological data) To study the relationship between neoplastic / preneoplastic lesions and pulmonary parenchyma reshaped by fibrosis.

Interventions

None listed

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Lung carcinoma * Idiopathic pulmonary fibrosis

Exclusion criteria

\- No tumor sample available

Design outcomes

Primary

MeasureTime frameDescription
Molecular profile of IPF-associated lung carcinomas1 month / 8 samplesNext generation sequencing of carcinomas with Ion S5 XL sequencer and Oncomine™ Comprehensive Panel

Secondary

MeasureTime frameDescription
Pathological characterization of lung carcinomas1 month / 8 samplesHistological classification of carcinomas and immunohistochemistry with lineage markers

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026